Neurovive’s Investigative Compound NV556 Shows Promise to Treat Mitochondrial Myopathy in Preclinical Study
News
NeuroVive Pharmaceutical AB’s investigative compound NV556 holds therapeutic potential for the treatment of mitochondrial myopathy, according to recent data of a preclinical study. Conducted in collaboration with researchers at Karolinska ... Read more